Search

Your search keyword '"Quint K"' showing total 237 results
Start Over Author "Quint K"
237 results on '"Quint K"'

1. Dermatologische problemen

Author

Habib, S. M., Quint, K. D., Benner, M. F., Genders, R. E., Secker, L. J., Lavrijsen, A. P. M., van Vugt, A.B., editor, Gaakeer, M.I., editor, Henny, W., editor, Kaasjager, H.A.H., editor, Motz, C., editor, Tan, E.C.T.H., editor, and Wulterkens, Th.W., editor

Published
2018
Full Text
View/download PDF

9. P13.05.A Image annotation guideline for invivo confocal laser endomicroscopy, interrater reliability and how to learn from medical consensus for machine learning algorithms

Author

Hewer, E, primary, Panitz, G, additional, Elsner, J, additional, Swamy von Zastrow, F, additional, Quint, K, additional, Eschbacher, J, additional, Sadeghi, D, additional, Ikeliani, I U, additional, Brunner, M, additional, Maragkou, T, additional, Abramov, I, additional, Xu, Y, additional, Belykh, E, additional, Mignucci-Jimenez, G, additional, Preul, M C, additional, and Schlegel, J, additional

Published
2022
Full Text
View/download PDF

10. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial

Author

Wind, S. S., Jansen, M. A. A., Rijsbergen, M., van Esdonk, M. J., Ziagkos, D., Cheng, W. C., Niemeyer-Van der Kolk, T., Korsten, J., Gruszka, A., Schmitz-Rohmer, D., Bonnel, D., Legouffe, R., Barré, F., Bekkenk, M. W., de Haas, E. R. M., Quint, K. D., Rolli, M., Streefkerk, H. J., Burggraaf, J., Vermeer, M. H., Rissmann, R., Wind, S. S., Jansen, M. A. A., Rijsbergen, M., van Esdonk, M. J., Ziagkos, D., Cheng, W. C., Niemeyer-Van der Kolk, T., Korsten, J., Gruszka, A., Schmitz-Rohmer, D., Bonnel, D., Legouffe, R., Barré, F., Bekkenk, M. W., de Haas, E. R. M., Quint, K. D., Rolli, M., Streefkerk, H. J., Burggraaf, J., Vermeer, M. H., and Rissmann, R.

Abstract

Mycosis fungoides (MF) is a subtype of CTCL with a low incidence and high medical need for novel treatments. The objective of this randomized, placebo-controlled, double-blinded, first-in-human study was to evaluate safety, efficacy, cutaneous and systemic pharmacokinetics (PK) of topical bimiralisib in healthy volunteers (HVs) and MF patients. In this trial, a total of 6 HVs and 19 early-stage MF patients were treated with 2.0% bimiralisib gel and/or placebo. Drug efficacy was assessed by the Composite Assessment of Index Lesion Severity (CAILS) score, supported by objective measuring methods to quantify lesion severity. PK blood samples were collected frequently and cutaneous PK was investigated in skin punch biopsies on the last day of treatment. Local distribution of bimiralisib in HVs showed a mean exposure of 2.54 µg/g in the epidermis. A systemic concentration was observed after application of a target dose of 2 mg/cm 2 on 400 cm 2, with a mean C avg of 0.96 ng/mL. Systemic exposure of bimiralisib was reached in all treated MF patients, and normalized plasma concentrations showed a 144% increased exposure compared to HVs, with an observed mean C avg of 4.49 ng/mL and a mean cutaneous concentration of 5.3 µg/g. No difference in CAILS or objective lesion severity quantification upon 42 days of once-daily treatment was observed in the MF patient group. In general, the treatment was well tolerated in terms of local reactions as well as systemic adverse events. In conclusion, we showed that topical bimiralisib treatment leads to (i) meaningful cutaneous drug levels and (ii) well-tolerated systemic drug exposure in MF patients and (iii) a lack of clinical efficacy, in need of further exploration due to numerous unknown factors, before depreciation of topical bimiralisib as a novel therapeutic drug for CTCLs.

Published
2022

15. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

Author

Quaglino, P. Prince, H. M. Cowan, R. Vermeer, M. and Papadavid, E. Bagot, M. Servitjie, O. Berti, E. Guenova, E. Stadler, R. Querfeld, C. Busschots, A. M. Hodak, E. and Patsatsi, A. Sanches, J. Maule, M. Yoo, J. Kevin, M. and Fava, P. Ribero, S. Zocchi, L. Rubatto, M. Fierro, M. T. Wehkamp, U. Marshalko, M. Mitteldorf, C. Akilov, O. Ortiz-Romero, P. Estrach, T. Vakeva, L. Enz, P. A. and Wobser, M. Bayne, M. Jonak, C. Rubeta, M. Forbes, A. and Bates, A. Battistella, M. Amel-Kashipaz, R. Vydianath, B. Combalia, A. Georgiou, E. Hauben, E. Hong, E. K. and Jost, M. Knobler, R. Amitay-Laish, I. Miyashiro, D. and Cury-Martins, J. Martinez, X. Muniesa, C. Prag-Naveh, H. and Stratigos, A. Nikolaou, V. Quint, K. Ram-Wolff, C. and Rieger, K. Stranzenbach, R. Szepesi, A. Alberti-Violetti, S. and Felicity, E. Cerroni, L. Kempf, W. Whittaker, S. and Willemze, R. Kim, Y. Scarisbrick, J. J.

Abstract

Background The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). Objectives To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. Methods In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. Results The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81 center dot 5%), while a smaller percentage (44 cases, 11 center dot 1%) received systemic therapy. Expectant observation was used in 7 center dot 3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0 center dot 001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0 center dot 001), higher modified Severity Weighted Assessment Tool (> 10, 15%

Published
2021

16. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

Author

Quaglino, P, Prince, HM, Cowan, R, Vermeer, M, Papadavid, E, Bagot, M, Servitjie, O, Berti, E, Guenova, E, Stadler, R, Querfeld, C, Busschots, AM, Hodak, E, Patsatsi, A, Sanches, J, Maule, M, Yoo, J, Kevin, M, Fava, P, Ribero, S, Zocchi, L, Rubatto, M, Fierro, MT, Wehkamp, U, Marshalko, M, Mitteldorf, C, Akilov, O, Ortiz-Romero, P, Estrach, T, Vakeva, L, Enz, PA, Wobser, M, Bayne, M, Jonak, C, Rubeta, M, Forbes, A, Bates, A, Battistella, M, Amel-Kashipaz, R, Vydianath, B, Combalia, A, Georgiou, E, Hauben, E, Hong, EK, Jost, M, Knobler, R, Amitay-Laish, I, Miyashiro, D, Cury-Martins, J, Martinez, X, Muniesa, C, Prag-Naveh, H, Stratigos, A, Nikolaou, V, Quint, K, Ram-Wolff, C, Rieger, K, Stranzenbach, R, Szepesi, A, Alberti-Violetti, S, Felicity, E, Cerroni, L, Kempf, W, Whittaker, S, Willemze, R, Kim, Y, Scarisbrick, JJ, Quaglino, P, Prince, HM, Cowan, R, Vermeer, M, Papadavid, E, Bagot, M, Servitjie, O, Berti, E, Guenova, E, Stadler, R, Querfeld, C, Busschots, AM, Hodak, E, Patsatsi, A, Sanches, J, Maule, M, Yoo, J, Kevin, M, Fava, P, Ribero, S, Zocchi, L, Rubatto, M, Fierro, MT, Wehkamp, U, Marshalko, M, Mitteldorf, C, Akilov, O, Ortiz-Romero, P, Estrach, T, Vakeva, L, Enz, PA, Wobser, M, Bayne, M, Jonak, C, Rubeta, M, Forbes, A, Bates, A, Battistella, M, Amel-Kashipaz, R, Vydianath, B, Combalia, A, Georgiou, E, Hauben, E, Hong, EK, Jost, M, Knobler, R, Amitay-Laish, I, Miyashiro, D, Cury-Martins, J, Martinez, X, Muniesa, C, Prag-Naveh, H, Stratigos, A, Nikolaou, V, Quint, K, Ram-Wolff, C, Rieger, K, Stranzenbach, R, Szepesi, A, Alberti-Violetti, S, Felicity, E, Cerroni, L, Kempf, W, Whittaker, S, Willemze, R, Kim, Y, and Scarisbrick, JJ

Abstract

BACKGROUND: The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). OBJECTIVES: To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. METHODS: In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. RESULTS: The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81·5%), while a smaller percentage (44 cases, 11·1%) received systemic therapy. Expectant observation was used in 7·3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0·001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0·001), higher modified Severity Weighted Assessment Tool (> 10, 15%; ≤ 10, 7%; P = 0·01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0·001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs. T1a/T2a, odds ratio 3·07) and FMF (odds ratio 2·83). The overall response rate (ORR) to first-line SDT was 73%, while the ORR to first-line systemic treatments was lower (57%) (P = 0·027). Health-related QoL improved significantly both in patients with responsive disease and in those with stable disease. CONCLUSIONS: Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.

Published
2021

21. Treatment of early‐stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

Author

Quaglino, P., primary, Prince, H.M., additional, Cowan, R., additional, Vermeer, M., additional, Papadavid, E., additional, Bagot, M., additional, Servitjie, O., additional, Berti, E., additional, Guenova, E., additional, Stadler, R., additional, Querfeld, C., additional, Busschots, A.M., additional, Hodak, E., additional, Patsatsi, A., additional, Sanches, J., additional, Maule, M., additional, Yoo, J., additional, Kevin, M., additional, Fava, P., additional, Ribero, S., additional, Zocchi, L., additional, Rubatto, M., additional, Fierro, M.T., additional, Wehkamp, U., additional, Marshalko, M., additional, Mitteldorf, C., additional, Akilov, O., additional, Ortiz‐Romero, P., additional, Estrach, T., additional, Vakeva, L., additional, Enz, P.A., additional, Wobser, M., additional, Bayne, M., additional, Jonak, C., additional, Rubeta, M., additional, Forbes, A., additional, Bates, A., additional, Battistella, M., additional, Amel‐Kashipaz, R., additional, Vydianath, B., additional, Combalia, A., additional, Georgiou, E., additional, Hauben, E., additional, Hong, E.K., additional, Jost, M., additional, Knobler, R., additional, Amitay‐Laish, I., additional, Miyashiro, D., additional, Cury‐Martins, J., additional, Martinez, X., additional, Muniesa, C., additional, Prag‐Naveh, H., additional, Stratigos, A., additional, Nikolaou, V., additional, Quint, K., additional, Ram‐Wolff, C., additional, Rieger, K., additional, Stranzenbach, R., additional, Szepesi, Á., additional, Alberti‐Violetti, S., additional, Felicity, E., additional, Cerroni, L., additional, Kempf, W., additional, Whittaker, S., additional, Willemze, R., additional, Kim, Y., additional, and Scarisbrick, J.J., additional

Published
2021
Full Text
View/download PDF

27. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, Willemze, R, Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, and Willemze, R

Abstract

BACKGROUND: Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES: To develop a prognostic index for MF. METHODS: Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS: In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS: This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.

Published
2019

28. MOLECULAR ANALYSIS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA LEG TYPE AT DIAGNOSIS AND RELAPSE - IMPLICATIONS FOR TARGETED THERAPIES

Author

Schrader, A. M. R., primary, de Groen, R. A. L., additional, Willemze, R., additional, Jansen, P. M., additional, Quint, K. D., additional, Cleven, A. H. G., additional, van Wezel, T., additional, van Eijk, R., additional, Ruano, D., additional, Tensen, C. P., additional, Hauben, E., additional, Woei-A-Jin, S., additional, Busschots, A. M., additional, Vermeer, M. H., additional, and Vermaat, J. S. P., additional

Published
2019
Full Text
View/download PDF

29. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, J.J., primary, Quaglino, P., additional, Prince, H.M., additional, Papadavid, E., additional, Hodak, E., additional, Bagot, M., additional, Servitje, O., additional, Berti, E., additional, Ortiz‐Romero, P., additional, Stadler, R., additional, Patsatsi, A., additional, Knobler, R., additional, Guenova, E., additional, Child, F., additional, Whittaker, S., additional, Nikolaou, V., additional, Tomasini, C., additional, Amitay, I., additional, Prag Naveh, H., additional, Ram‐Wolff, C., additional, Battistella, M, additional, Alberti‐Violetti, S., additional, Stranzenbach, R., additional, Gargallo, V., additional, Muniesa, C., additional, Koletsa, T., additional, Jonak, C., additional, Porkert, S., additional, Mitteldorf, C., additional, Estrach, T., additional, Combalia, A., additional, Marschalko, M., additional, Csomor, J., additional, Szepesi, A., additional, Cozzio, A., additional, Dummer, R., additional, Pimpinelli, N., additional, Grandi, V., additional, Beylot‐Barry, M., additional, Pham‐Ledard, A., additional, Wobser, M., additional, Geissinger, E., additional, Wehkamp, U., additional, Weichenthal, M., additional, Cowan, R., additional, Parry, E., additional, Harris, J., additional, Wachsmuth, R., additional, Turner, D., additional, Bates, A., additional, Healy, E., additional, Trautinger, F., additional, Latzka, J., additional, Yoo, J., additional, Vydianath, B., additional, Amel‐Kashipaz, R., additional, Marinos, L., additional, Oikonomidi, A., additional, Stratigos, A., additional, Vignon‐Pennamen, M.‐D., additional, Battistella, M., additional, Climent, F., additional, Gonzalez‐Barca, E., additional, Georgiou, E., additional, Senetta, R., additional, Zinzani, P., additional, Vakeva, L., additional, Ranki, A., additional, Busschots, A.‐M., additional, Hauben, E., additional, Bervoets, A., additional, Woei‐A‐Jin, F.J.S.H., additional, Matin, R., additional, Collins, G., additional, Weatherhead, S., additional, Frew, J., additional, Bayne, M., additional, Dunnill, G., additional, McKay, P., additional, Arumainathan, A., additional, Azurdia, R., additional, Benstead, K., additional, Twigger, R., additional, Rieger, K., additional, Brown, R., additional, Sanches, J.A., additional, Miyashiro, D., additional, Akilov, O., additional, McCann, S., additional, Sahi, H., additional, Damasco, F.M., additional, Querfeld, C., additional, Folkes, A., additional, Bur, C., additional, Klemke, C.‐D., additional, Enz, P., additional, Pujol, R., additional, Quint, K., additional, Geskin, L., additional, Hong, E., additional, Evison, F., additional, Vermeer, M., additional, Cerroni, L., additional, Kempf, W., additional, Kim, Y., additional, and Willemze, R., additional

Published
2018
Full Text
View/download PDF

30. Ooorzakelijke HPV-typen van anuscarcinoom

Author

Gosens, K., Richel, O., Prins, J. M., de Vries, H. J. C., de Koning, M. N. C., van den Munckhof, H. A. M., van Noesel, C. J. M., Quint, K. D., Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Graduate School, Dermatology, Other departments, Infectious diseases, Amsterdam Public Health, and Pathology

Published
2016

32. De venereologie als onderdeel van ons vakgebied, gooi het kind niet met het badwater weg!

Author

Quint, K. D., Lavrijsen, A. P.M., Starink, M. V., Grijsen, M. L., Komen, D. J.C., Sanders, C. J.G., Hogewoning, A. A., Sirgudsson, V., Van Der Ham, R., Van Der Vleuten, C. J.M., Van Der Snoek, E. M., Cairo, I., Kardaun, S. H., De Vries, H. J.C., Graduate School, Dermatology, Amsterdam institute for Infection and Immunity, and Amsterdam Public Health

Published
2015

33. The strong antiproliferative effects of FTY720 (fingolimod) in glioblastoma cells in vitro

Author

Kolodziej, M, Al-Barim, B, Stein, M, Reinges, M, Uhle, F, Quint, K, and Uhl, E

Subjects
antiproliferative effect, ddc: 610, glioblastoma, lipids (amino acids, peptides, and proteins), fingolimod, 610 Medical sciences, Medicine
Abstract

Objective: The sphingosine-1-phosphate (S1P) pathway is mediated through G-protein coupled receptors signaling to the PI3K/Akt, Rho/ROCK and Ras/ERK/MAPK cascades. Previously it was shown that sphingosine kinase 1 and S1P-receptor 1 expression influence survival of glioma patients.[for full text, please go to the a.m. URL], 65. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)

Published
2014
Full Text
View/download PDF

37. The sphingosine-1-phosphate analogon FTY720 has potent antiproliferative effects on glioblastoma cell line

Author

Kolodziej, M, Al-Barim, B, Stein, M, Reinges, M, Uhl, E, and Quint, K

Subjects
FTY720, ddc: 610, glioblastoma cell lines, sphingosine-1-phosphate, lipids (amino acids, peptides, and proteins), 610 Medical sciences, Medicine
Abstract

Objective: The sphingosine-1-phosphate (S1P) pathway is involved in cell survival, growth, migration and angiogenesis. While overexpressed in gliomas, we and others have previously shown the influence of sphingosne kinase 1 and S1P-receptor 1 expression on survival of glioma patients. Here we investigate[for full text, please go to the a.m. URL], 64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)

Published
2013
Full Text
View/download PDF

38. Roscovitine presents tumor-suppressive effect on glioblastoma cell lines

Author

Kolodziej, M, Götz, C, Strik, H, Uhl, E, and Quint, K

Subjects
cell--lines, ddc: 610, glioblastoma, 610 Medical sciences, Medicine, roscovitine
Abstract

Objective: Roscovitine, a purine analogue and cyclin-dependent kinase (CDK) inhibitor, shows strong antiproliferative and proapoptotic effects in solid and hematologic cancers, such as non small-cell lung cancer and various lymphomas. It targets preferentially CDK2, 7 and 9, which are also overexpressed[for full text, please go to the a.m. URL], 64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)

Published
2013
Full Text
View/download PDF

39. Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group.

Author

Melchers, R. C., Willemze, R., Bekkenk, M. W., de Haas, E. R. M., Horvath, B., van Rossum, M. M., Sanders, C. J. G., Veraart, J. C. J. M., Vermeer, M. H., and Quint, K. D.

Subjects
T-cell lymphoma, METHOTREXATE, DRUG therapy, CELL proliferation, MONOCLONAL antibodies, THERAPEUTICS
Abstract

Summary: Background: There is no consensus on the treatment of multifocal primary cutaneous anaplastic large cell lymphoma (C‐ALCL). Radiotherapy (RT) and methotrexate (MTX) are the current treatment options, but their efficacy is unknown. Recently, targeted therapies showed promising results in C‐ALCL, and may therefore be an attractive first choice of treatment. Objectives: To assess the efficacy of conventional treatment strategies for patients with multifocal C‐ALCL, and to define which patients may require novel targeted therapies. Methods: In this multicentre study, treatment was evaluated in patients initially presenting (n = 24) or relapsing with multifocal C‐ALCL (n = 17; 23 relapses). Distinction was made between patients with five or less lesions (n = 36) and more than five lesions (n = 11). Results: Treatments most commonly used were RT (n = 21), systemic chemotherapy (n = 9) and low‐dose MTX (n = 7) with complete response rates of 100%, 78% and 43%, respectively, and an overall response rate of 100%, 100% and 57%, respectively. Four patients showed complete spontaneous regression. In total, 16 of 24 patients (67%) first presenting with multifocal C‐ALCL relapsed, including all five patients initially treated with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone). Compared with patients presenting with two to five skin lesions, patients presenting with more than five lesions had a higher chance of developing extracutaneous relapse (56% vs. 20%) and more often died of lymphoma (44% vs. 7%). Conclusions: Patients with five or less lesions should be treated with low‐dose RT (2 × 4 Gy). Maintenance low‐dose MTX (20 mg weekly) is a suitable option in patients with more than five lesions. Targeted therapies may be considered in rare patients who are refractory to MTX or patients developing extracutaneous disease. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

40. Developing and validating the Cutaneous WARTS (CWARTS) diagnostic tool: a novel clinical assessment and classification system for cutaneous warts.

Author

Hogendoorn, G. K., Bruggink, S. C., Hermans, K. E., Kouwenhoven, S. T. P., Quint, K. D., Wolterbeek, R., Eekhof, J. A. H., de Koning, M. N. C., Rissmann, R., Burggraaf, J., and Bouwes Bavinck, J. N.

Subjects
ERYTHEMA, PLANTAR warts, DISEASE prevalence, PAPILLOMAVIRUSES, INTRACLASS correlation
Abstract

Summary: Background : The clinical appearance of cutaneous warts is highly variable and not standardized. Objectives : To develop and validate a reproducible clinical tool for the standardized assessment of cutaneous warts to distinguish these lesions accurately. Methods : Nine morphological characteristics were defined and validated regarding intra‐ and interobserver agreement. Based on literature and semistructured interviews, a systematic dichotomous assessment tool, the Cutaneous WARTS (CWARTS) diagnostic tool was developed. The validation consisted of two independent parts performed with photographs from the recent WARTS‐2 trial. In part A, the CWARTS diagnostic tool was tested by 28 experienced physicians who assessed photographs of 10 different warts to investigate interobserver concordance. In part B, morphological characteristics were validated by masked and independent scoring of 299 photographs by six different observers. Part B also entailed reassessment of the photographs after at least 1 week. The primary outcome measurement was the intraclass correlation coefficient (ICC). Results : Presence of black dots (capillary thrombosis) had the greatest ICC (0·85) for interobserver agreement in part A, followed by arrangement (0·65), presence of border erythema (0·64) and sharpness of the border (0·60). In part B, results were similar for interobserver agreement with presence of black dots having the highest ICC (0·68), followed by border erythema (0·64), arrangement (0·58) and colour (0·55). For intraobserver agreement, presence of black dots had the highest agreement (0·70), followed by presence of border erythema (0·694) and colour (0·59). Conclusions : Wart phenotype can be reliably assessed using the CWARTS diagnostic tool. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

41. Morphological characteristics and human papillomavirus genotype predict the treatment response in cutaneous warts.

Author

Hogendoorn, G. K., Bruggink, S. C., de Koning, M. N. C., Eekhof, J. A. H., Hermans, K. E., Rissmann, R., Burggraaf, J., Wolterbeek, R., Quint, K. D., Kouwenhoven, S. T. P., and Bouwes Bavinck, J. N.

Subjects
PAPILLOMAVIRUSES, WARTS treatment, GENOTYPES, VIRAL genomes, VIRUS morphology, MEDICAL decision making
Abstract

Summary: Background: Cutaneous warts have a cure rate after therapy of no more than approximately 50%. Recently, we developed and validated a standard assessment tool for warts (Cutaneous WARTS diagnostic tool, CWARTS) based on phenotypical characteristics. Objectives: To assess whether patient and morphological wart characteristics predict the human papillomavirus (HPV) type in a specific wart and whether these characteristics as well as the HPV type predict a favourable treatment response. Methods: Photographs were used to score nine morphological wart characteristics using the newly developed CWARTS tool. Genotyping of 23 wart‐associated HPV types was performed using the hyperkeratotic skin lesion–polymerase chain reaction/multiplex genotyping assay. The results were correlated with a favourable response to treatment with monochloroacetic acid, cryotherapy or a combination of cryotherapy and salicylic acid. Odds ratios were calculated using logistic regression in a generalized estimating equations model. Results: Black dots (capillary thrombosis) strongly predicted the presence of any HPV type in a wart. From all characteristics tested, the HPV type most strongly predicted the treatment response when the warts were treated with monochloroacetic acid or a combination of cryotherapy and salicylic acid with a significantly decreased treatment response if the warts contained HPVs of the alpha genus (HPV2, HPV27 or HPV57). When cryotherapy alone was used for common warts, HPV type did not play a role, but cryotherapy was less effective in the presence of callus and when the wart was located deeper in the skin. Conclusions: Morphological characteristics of the warts and the HPV genotype influence treatment outcome and thus potentially influence future treatment decisions for common and plantar warts. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

43. The role of sphingosine kinase isoforms and their receptors in growth of primary, secondary and recurrent glioblastoma

Author

Kolodziej, M, Stiel, N, Quint, K, Ocker, M, Strik, H, Benes, L, and Nimsky, C

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Objective: Sphingosine 1-phosphate (S1P), a sphingolipid metabolite playing an important role in the regulation of cell survival, growth, migration and angiogenesis, acts both inside the cells and as an extracellular mediator through binding to five G protein-coupled receptors, S1P1-5. Sphingosine kinase[for full text, please go to the a.m. URL], 62. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgen (PNCH)

Published
2011
Full Text
View/download PDF

45. Significantly higher serologic responses of Chlamydia trachomatis B group serovars versus C and I serogroups

Author

Bax, C. J., Dörr, P. J., Morré, S. A., Mutsaers, J. A., Oostvogel, P. M., Sander Ouburg, Peters, R. P. H., Pleijster, J., Quint, K. D., Quint, W. G. V., Leeuwen, A. P., Verweij, S. P., Medical Microbiology and Infection Prevention, Internal medicine, Division 6, Pathology, CCA - Immuno-pathogenesis, Medical Microbiology and Infection Control, and Obstetrics and gynaecology

Subjects
bacterial infections and mycoses
Abstract

Chlamydia trachomatis serovars are divided into three serogroups, namely serogroup B, serogroup I (Intermediate) and serogroup C, and subsequently into 19 different serovars. Worldwide, serogroup B is the most prevalent followed by serogroup I. Clear differences have been observed in the duration of infection and growth kinetics between serovars from different serogroups in murine and cell culture models. Reasons for these observed differences are bacterial and host related, and are not well understood. The aim of this study was to determine the differences in immunoglobulin (Ig) G responses between the three serogroups in a group of patients infected with different serovars. Serovars were assessed from 235 C. trachomatispositive patients and quantitative IgG responses were determined. Analyses of variance were used to compare the IgG responses between the three serogroups. Of the serovars, 46% were B group (with serovar E the most prevalent: 35.3%), 39.6% were I group and 14.3% were C group. A highly significant difference in serologic response was shown when comparing the mean IgG concentrations (AU/mL) of patients having serovars in the most prevalent serogroup compared to the other serogroups: B = 135, C = 46 and I = 60 (B vs. C and B vs. I, P < 0.001). In conclusion, the most prevalent serovars generate the highest serologic responses.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results